This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ryzolt

Purdue Pharma LP

Drug Names(s): Tramadol OAD, Once-daily tramadol, Tridural, Tradorec XL, NS-24, Onetram

Description: Labopharm is developing a once-daily formulation of tramadol (Tramadol OAD). Tramadol is a non-scheduled, centrally acting analgesic for the treatment of pain. The once-daily tramadol product consists of a dual matrix delivery system designed to provide both rapid and sustained drug release to maintain blood levels within the therapeutic range. Although the mode of action of tramadol is not completely understood, several complementary mechanisms appear applicable: mild agonism of parent and M1 metabolite to µ-opioid receptors, weak inhibition of reuptake of norepinephrine and serotonin, and modulation of the GABAergic system.

Deal Structure: Angelini and Esteve
In April 2003, Labopharm announced that through its wholly owned subsidiary, Labopharm Europe Limited, it secured marketing agreements for Italy with Gruppo Angelini and for Spain and Portugal with Esteve S.A. for its once-daily version of the analgesic tramadol.

Under terms of the revenue sharing agreements, Labopharm will grant Angelini and Esteve the exclusive right to market and sell once-daily tramadol in Italy and its related territories and Spain, Portugal and their related territories, respectively. Labopharm will supply Angelini and Esteve with finished packaged product through its Labopharm Europe subsidiary.

In August 2003, Labopharm announced that, through its Labopharm Europe subsidiary, it executed a definitive distribution and licensing agreement with Esteve S.A. for Spain and Portugal for its once-daily version of the analgesic tramadol.

Under terms of the agreement, Labopharm will receive payments for achieving certain milestones...See full deal structure in Biomedtracker

Partners: Johnson & Johnson Sanofi Nippon Shinyaku Co., Ltd. SciClone Pharmaceuticals, Inc. Endo International plc Pfizer Inc.


Ryzolt News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug